83
2
142
2
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
TP1008 |
Neurokinin A
α-Neurokinin,Substance K,神经激肽A,Neuromedin L |
Neurokinin receptor | GPCR/G Protein; Neuroscience |
Neurokinin A (NKA) 是速激肽家族的一种肽类神经递质,是人体气管道和胃肠道组织中的主要介体,可通过 NK-2受体发挥作用。 | |||
TP1385 |
Neurokinin A(4-10) TFA(97559-35-8 free base)
Neurokinin A(4-10) TFA |
Neurokinin receptor | GPCR/G Protein; Neuroscience |
Neurokinin A(4-10) TFA(97559-35-8 free base) 是一种速激肽 NK2 受体激动剂。 | |||
T7559 |
Neurokinin A(4-10)
神经激肽 A (4-10),Neurokinin A(4-10)(TFA) |
Neurokinin receptor | GPCR/G Protein; Neuroscience |
Neurokinin A(4-10) 是一种速激肽NK2受体激动剂。 | |||
T33654 |
Neurokinin A-OH
Nka OH,NkaOH,Nka-OH |
Others | Others |
Neurokinin A-OH is the C-terminal free acid derivative of neurokinin A. | |||
TP1100 |
[bAla8]-Neurokinin A(4-10)
MEN 10210 |
||
[bAla8]-Neurokinin A(4-10) is a neurokinin 2 (NK2) receptor agonist. | |||
T33653 |
Neurokinin A (4-10), nle(10)-
10-Nle-neurokinin A (4-10) |
Others | Others |
Neurokinin A (4-10), nle(10)- is a neurologically active peptide translated from the pre-protachykinin gene. Neurokinin A has many excitatory effects on mammalian nervous systems and on the mammalian inflammatory and pain responses. | |||
T75729 |
Neurokinin A TFA
|
||
Neurokinin A TFA (Substance K TFA) 为速激肽家族内的一种肽类神经递质,主要通过NK-2受体发挥作用,在人类气道和胃肠道组织中充当关键介体。 | |||
T64680 |
Neurokinin A trifluoroacetate
|
Others | Others |
Neurokinin A trifluoroacetate 是一种有用的有机化合物,可用于生命科学领域的相关研究,其产品编号为 T64680。 | |||
T80915 |
Tyr0-Neurokinin A
|
||
Tyr0-Neurokinin A,一种神经肽,隶属于速激肽家族,作为Tacr2的激动剂,适用于胰岛素抵抗、肥胖和糖尿病研究领域。 | |||
T75742 |
Neurokinin A(4-10) TFA
|
||
Neurokinin A (4-10) TFA 是速激肽NK2受体激动剂。 | |||
T76428 |
(β-Ala8)-Neurokinin A (4-10)
|
||
(β-Ala8)-Neurokinin A (4-10) 是一种神经肽,是一种有效的选择性 NK-2(Neurokinin Receptor) 速激肽受体激动剂。 | |||
T76635 |
(Trp7,β-Ala8)-Neurokinin A (4-10)
|
||
(Trp7,β-Ala8)-Neurokinin A (4-10) 是一种有效的neurokinin-3 (NK3)拮抗剂。 | |||
T76426 |
[Lys5,MeLeu9,Nle10]Neurokinin A(4-10)
|
||
[Lys5,MeLeu9,Nle10]Neurokinin A(4-10) (LMN-NKA),Neurokinin A 的类似物,是一种选择性且有效的 NK2R 激动剂。[Lys5,MeLeu9,Nle10]Neurokinin A(4-10) 具有促运动活性。[Lys5,MeLeu9,Nle10]Neurokinin A(4-10) 可用于研究 NK-2 受体在多种组织平滑肌收缩中的作用。 | |||
T10056 |
Neurokinin antagonist 1
|
Neuropeptide Y Receptor | GPCR/G Protein; Neuroscience |
Neurokinin antagonist 1是一种有效的是神经肽拮抗剂,可用于研究神经系统疾病。 | |||
T76436 |
[MePhe7]-Neurokinin B
|
||
[MePhe7]-Neurokinin B为NK-3受体(NK3R)激动剂,具有3 nM的IC50值。通过激活神经激肽3受体,[MePhe7]-Neurokinin B能够调节脉冲促性腺激素释放激素(GnRH)的分泌,成为调控该过程的潜在调节剂。 | |||
T80914 |
Tyr0-Neurokinin B
Tyr-NKB |
||
Tyr0-Neurokinin B (Tyr-NKB)为Neurokinin B的类似物,具有引发膀胱收缩的生物活性。 | |||
T76429 |
Neurokinin Receptor (393-407), rat
|
||
Neurokinin Receptor(393-407), rat (SPR393–407) 是一段属于大鼠神经激肽1受体(NK1R)的特定肽。它与P物质(SP)结合后,通过内吞作用迅速被NK1R内化,并循环至质膜。此化合物主要应用于神经源性炎症研究领域。 | |||
T76427 |
(D-Pro2,D-Trp6,8,Nle10)-Neurokinin B
|
||
(D-Pro2,D-Trp6,8,Nle10)-Neurokinin B 是 Neurokinin B(Neurokinin Receptor) 的竞争性拮抗剂,pA2 为 5.5,对 Substance P 或 Neurokinin A 没有影响。 | |||
T29157 |
WIN 51,708
WIN51,708,WIN-51,708 |
Neurokinin receptor | GPCR/G Protein; Neuroscience |
WIN 51,708 是一种神经激肽受体(NK1)拮抗剂。 | |||
T22811L |
GR 94800 acetate
GR 94800 acetate (141636-65-9 free base) |
Neurokinin receptor | GPCR/G Protein; Neuroscience |
GR 94800 acetate 是一种有效的选择性神经激肽 2(NK-2) 拮抗剂。 | |||
T68068 |
Ezlopitant
CJ 11974,CJ-11974,CJ11974 |
Neurokinin receptor | GPCR/G Protein; Neuroscience |
Ezlopitant (CJ-11974) 是一种基于喹啉的原型 NK1受体拮抗剂 CP-96345的衍生物。 | |||
T1743 |
Aprepitant
MK-869,MK-0869,阿瑞匹坦,L-754030,Aprepitant` |
HIV Protease; Antibacterial; Antibiotic; Neurokinin receptor | GPCR/G Protein; Microbiology/Virology; Neuroscience; Proteases/Proteasome |
Aprepitant (Aprepitant`) 是选择性和高亲和力的神经激肽1受体拮抗剂,Kd 值为86 pM。 | |||
T7209 |
Maropitant
马罗匹坦,马罗皮坦 |
Neurokinin receptor | GPCR/G Protein; Neuroscience |
Maropitant 是一种可口服的选择性神经激肽受体拮抗剂,通过阻止催吐中心与化学感受器触发区中 P 物质的结合而起作用,有预防呕吐作用。 | |||
TP1087 |
Substance P
Neurokinin P,P物质 |
Endogenous Metabolite; Neurokinin receptor | GPCR/G Protein; Metabolism; Neuroscience |
Substance P (Neurokinin P) 是一种神经肽,其内源性受体是神经激肽1受体,在中枢神经系统中作为神经递质和神经调节剂。 | |||
T38144 |
Elinzanetant
|
Neurokinin receptor | GPCR/G Protein; Neuroscience |
Elizanetant 是有效的神经激肽受体拮抗剂,在精神分裂症研究中有价值。 | |||
T68068L |
(R)-CJ 11974
|
Neurokinin receptor | GPCR/G Protein; Neuroscience |
T6905 |
Netupitant
Ro 67-31898/000,奈妥吡坦,CID 6451149 |
Neurokinin receptor | GPCR/G Protein; Neuroscience |
Netupitant (CID 6451149) 是一种高效选择性、可口服的神经激肽 1 受体 (NK1) 拮抗剂,具有止吐作用,在 CHO 细胞中对 hNK1的 Ki 值为 0.95 nM。 | |||
T25616 |
Lanepitant 2HCl
LY303870 dihydrochloride,LY 303870 dihydrochloride,LY-303870 dihydrochloride,Lanepitant dihydrochloride |
Neurokinin receptor | GPCR/G Protein; Neuroscience |
Lanepitant 2HCl 是一种非肽类神经激肽-1 受体拮抗剂,具有镇痛和抗炎活性。Lanepitant 2HCl 抑制 P 物质与神经激肽-1 受体的结合,抑制神经源性炎症和疼痛传递,可用于研究偏头痛等疼痛性神经病变类疾病。 | |||
TP1851L |
Scyliorhinin II acetate
|
Neurokinin receptor | GPCR/G Protein; Neuroscience |
Scyliorhinin II acetate 是大鼠大脑皮层神经激肽 3 (NK3) 受体 (Ki = 2.5 nM) 的选择性激动剂。 | |||
T19518L |
Physalaemin acetate
|
Neurokinin receptor | GPCR/G Protein; Neuroscience |
Physalaemin acetate 是一种非哺乳动物速激肽,在选择性结合神经激肽 1 (NK1) 受体时具有高亲和力。 | |||
T25615 |
Lanepitant
LY303870,LY-303870,LY 303870 |
Others | Others |
Lanepitant (LY303870) 是一种非肽类神经激肽-1(NK-1)拮抗剂,具有镇痛活性,可抑制神经源性硬脑膜炎症,可用于预防偏头痛。 | |||
TP1086 |
Men 10376 TFA(135306-85-3,free)
Men 10376 TFA,Neurokinin-2 receptor antagonist TFA |
Neurokinin receptor | GPCR/G Protein; Neuroscience |
Men 10376 TFA(135306-85-3,free) (Neurokinin-2 receptor antagonist TFA) 是一种有效的选择性速激肽 nk-2 受体拮抗剂,对大鼠小肠 nk-2 受体的 K I 值为 4.4 M。 | |||
T69140 |
Burapitant
SSR 240600 |
Neurokinin receptor | GPCR/G Protein; Neuroscience |
Burapitant(SSR 240600)是一种新型非肽速激肽神经激肽 1 (NK) 受体拮抗剂,具有抗焦炉和抗抑郁活性。 | |||
T8235 |
L-732138
|
Neurokinin receptor | GPCR/G Protein; Neuroscience |
L-732138 是选择性有效和竞争性神经激肽-1受体拮抗剂,IC50为 2.3 nM,可减轻痛觉过敏并具有抗肿瘤作用。它在克隆的人 NK-1受体中的效力比在克隆大鼠 NK-1受体中高 200 倍,比人类 NK-2 和 NK-3 受体高 1000 倍以上。 | |||
T3724 |
Rolapitant hydrochloride
Rolapitant HCl,罗拉匹坦盐酸盐 |
Neurokinin receptor | GPCR/G Protein; Neuroscience |
Rolapitant (SCH619734) hydrochloride 是一种高效选择性和具有口服活性的神经激肽 1 (NK1) 受体拮抗剂,Ki 值为 0.66 nM。Rolapitant hydrochloride (Rolapitant HCl) 不与 CYP3A4 产生互作。Rolapitant hydrochloride 在雪貂呕吐模型中显示出强效的中枢介导的止吐活性。 | |||
T9417L |
gamma-preprotachykinin amide (72-92) acetate
gamma-preprotachykinin amide (72-92) acetate (114882-65-4 Free base) |
Others | Others |
gamma-preprotachykinin amide (72-92) acetate 是一种 21 个氨基酸的肽,属于速激肽 (TK) 家族,在其 C 末端序列中包括神经激肽 A (NKA)。它对中枢 NK-2 受体的亲和力高于 NKA;它对 NK-1 受体的亲和力较低,但是,它有效地刺激唾液分泌,这是由 NK-1 受体激活介导的。 | |||
T3716 |
Rolapitant
罗拉吡坦,SCH619734,罗拉匹坦 |
Neurokinin receptor | GPCR/G Protein; Neuroscience |
Rolapitant (SCH619734) 是一种高效选择性具有口服活性的神经激肽 1 受体抑制剂,Ki 值为0.66 nM。 | |||
T24285 |
L 363851
L363851,L-363851,L363,851,L 363,851,L-363,851 |
Others | Others |
L 363851 is a neurokinin B agonist. | |||
T29234 |
ZM 253270
ZM253270,ZM-253270 |
Others | Others |
ZM 253270 is an nonpeptide neurokinin A antagonist. | |||
T68556 |
GW679769
|
Others | Others |
GW679769 is a neurokinin-1 receptor antagonist. | |||
T24447 |
Men 10208
Men-10208,Thr-asp-tyr-trp-val-trp-trp-arg-NH2,Men10208 |
Others | Others |
Men 10208 is an antagonist of the neurokinin A receptor. | |||
T69184 |
Figopitant
|
Others | Others |
Figopitant is a tachykinin neurokinin-1 antagonist. | |||
T69852 |
CS-003 HCl
|
Others | Others |
CS-003 HCl is a TNRA - triple neurokinin receptor antagonist. | |||
T70455 |
Nolpitantium besilate
|
Others | Others |
Nolpitantium besilate is a neurokinin-1 receptor antagonist. | |||
TP2155 |
Substance P TFA
Neurokinin P TFA |
Others | Others |
Substance P TFA (Neurokinin P TFA) is a neuropeptide, acting as a neurotransmitter and as a neuromodulator in the CNS, targeting the neurokinin 1 receptor (NK1-receptor, NK1R). | |||
T33264 |
Mdl 28564
Mdl28,564,Mdl-28,564,Mdl 28,564,Mdl28564,Mdl-28564 |
Others | Others |
Mdl 28564 is a neurokinin A analog. | |||
T69295 |
DNK 333
|
Others | Others |
DNK 333 is a dual neurokinin NK1/NK2 receptor antagonist. | |||
T69720 |
CJ-17493 (free base)
|
Others | Others |
CJ-17493 (free base) is a Neurokinin-1 Receptor Antagonist. | |||
TP1363 |
Neurokinin B
|
||
Neurokinin B (NKB) belongs in the family of tachykinin peptides. Neurokinin B is implicated in a variety of human functions and pathways such as the secretion of gonadotropin-releasing hormone. | |||
T70587 |
CJ-12255
|
Others | Others |
CJ-12255 is a Neurokinin-1 Receptor Antagonist. |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T38033 |
Benzomalvin B
|
Others | Others |
Benzomalvin B is a fungal metabolite originally isolated from Penicillium. It acts as an antagonist of neurokinin-1 (NK1) receptors, inhibiting binding of substance P by 24% in vitro when used at a concentration of 100 μg/ml. | |||
T71833 |
Acetylaszonalenin
|
Others | Others |
Acetylaszonalenin is a fungal metabolite that has been found in A. flavipes.1 It acts as an antagonist of neurokinin-1 (NK1) receptors, inhibiting binding of substance P with a Ki value of 170 μM. |
Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPJ-00892 |
TAC1 Protein, Human, Recombinant (His)
PPT,Protachykinin-1,TAC1 |
Human | E. coli |
Protachykinin-1(TAC1) is a secreted protein and belongs to the tachykinin family. TAC1 is encoded by the TAC1 gene. This gene encodes four products of the tachykinin peptide hormone family, substance P and neurokinin A, as well as the related peptides, neuropeptide K and neuropeptide gamma. These hormones are thought to function as neurotransmitters which interact with nerve receptors and smooth muscle cells. They are known to induce behavioral responses and function as vasodilators and secretag... | |||
TMPJ-01379 |
TAC3 Protein, Human, Recombinant (His)
Neurokinin-B,Tachykinin-3,UNQ585/PRO1155,N... |
Human | E. coli |
Tachykinin 3 (TAC3) is a secreted protein that belongs to the Tachykinin family. Tachykinins are active peptides that excite neurons and evoke behavioral responses; they are potent vasodilators and secretagogues, and contract many smooth muscles in pregnancy. TAC3 is primarily expressed in the central and peripheral nervous systems and functions as a neurotransmitter. It is also expressed in the outer syncytiotrophoblast of the placenta and may be associated with pregnancy-induced hypertension ... | |||
TMPK-01419 |
Peptide Ready HLA-A*03:01&B2M Monomer Protein, Human, MHC (His & Avi), Biotinylated
MHC,HLA-A*02:01,Peptide Ready |
Human | HEK293 Cells |
Peptide Ready HLA-A*03:01&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*03:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01426 |
Peptide Ready HLA-A*11:01&B2M Monomer Protein, Human, MHC (His & Avi)
HLA-A*02:01,Peptide Ready,MHC |
Human | HEK293 Cells |
Peptide Ready HLA-A*11:01&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*11:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01421 |
Peptide Ready HLA-A*02:01&B2M Monomer Protein, Human, MHC (His & Avi), Biotinylated
HLA-A*02:01,MHC,Peptide Ready |
Human | HEK293 Cells |
HLA-A*02:01&B2M&Peptide ready Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*02:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01420 |
Peptide Ready HLA-A*03:01&B2M Monomer Protein, Human, MHC (His & Avi)
Peptide Ready,MHC,HLA-A*02:01 |
Human | HEK293 Cells |
Peptide Ready HLA-A*03:01&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*03:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01410 |
Peptide Ready HLA-A*24:02&B2M Monomer Protein, Human, MHC (His & Avi)
HLA-A,MHC,Peptide Ready |
Human | HEK293 Cells |
Peptide Ready HLA-G&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-G. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01422 |
Peptide Ready HLA-A*02:01&B2M Monomer Protein, Human, MHC (His & Avi)
Peptide Ready,MHC,HLA-A*02:01 |
Human | HEK293 Cells |
Peptide Ready HLA-A*02:01&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*02:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01425 |
Peptide Ready HLA-A*11:01&B2M Monomer Protein, Human, MHC (His & Avi), Biotinylated
MHC,HLA-A*02:01,Peptide Ready |
Human | HEK293 Cells |
Peptide Ready HLA-A*11:01&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*11:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01415 |
APC-equivalent Peptide Ready HLA-A*02:01&B2M Tetramer Protein, Human, MHC (His)
Peptide Ready,HLA-A*02:01,MHC |
Human | HEK293 Cells |
Peptide Ready HLA-A*02:01&B2M Tetramer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*02:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01409 |
Peptide Ready HLA-A*24:02&B2M Monomer Protein, Human, MHC (His & Avi), Biotinylated
Peptide Ready,MHC,HLA-A |
Human | HEK293 Cells |
Peptide Ready HLA-G&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-G. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01510 |
HLA-A*03:01&B2M&KRAS WT (VVVGAGGVGK) Tetramer Protein, Human, MHC (His & Avi)
NS,NS3,KRAS2,RASK2,MHC,RALD,K-R |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. | |||
TMPK-01463 |
HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Monomer Protein, Human, MHC (His & Avi)
C-K-RAS,KI-RAS,KRAS1,K-RA |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01429 |
HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated
MHC,K-Ras 2,NS,K-RAS4A,KRA |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01500 |
HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Monomer Protein, Human, MHC (His & Avi)
CTAG1,CT6.1,CTAG1B,LAGE2A |
Human | HEK293 Cells |
NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit spontaneous humoral and cellular immune responses, together with its restricted expression pattern, have rendered it a good candidate target for cancer immunotherapy. | |||
TMPK-01473 |
HLA-A*24:02&B2M&MAGE-A3 (IMPKAGLLI) Monomer Protein, Human, MHC (His & Avi), Biotinylated
CT1.3,MAGE-3,MZ2-D,MZ2D,HLA-A2402... |
Human | HEK293 Cells |
Melanoma antigen gene A3 (MAGE-A3) is one of the most immunogenic cancer testis antigens and is common in various types of cancers. MAGE-A3 can be considered as a predictor for poor prognosis and an option for vaccine immunotherapy in patients with PCa. | |||
TMPK-01518 |
HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein, Human, MHC (His & Avi)
MHC,NS,KRAS1,K-RAS2A,GTPa |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01527 |
HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi)
NS,RALD,C-K-RAS,RASK2,K-RA |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01408 |
HLA-A*02:01&B2M&KRAS G12V (KLVVVGAVGV) Monomer Protein, Human, MHC (His & Avi), Biotinylated
RALD,KRAS1,KRAS2,K-RAS2B... |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01433 |
HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Tetramer Protein, Human, MHC (His & Avi)
GTPase Kras,NS3,K-Ras 2,K-RA<... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01455 |
HLA-A*02:01&B2M&PRAME (SLLQHLIGL) Monomer Protein, Human, MHC (His & Avi)
OIP4,PRAME,OIP-4,MAPE |
Human | HEK293 Cells |
PRAME (PReferentially expressed Antigen in MElanoma) is a melanoma-associated antigen expressed in cutaneous and ocular melanomas and some other malignant neoplasms, while its expression in normal tissue and benign tumors is limited. | |||
TMPK-01401 |
HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi)
MHC,CFC2,K-Ras 2,RALD,K-RAS4A... |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. | |||
TMPK-01488 |
HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi)
K-RAS4A,MHC,GTPase Kras,... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. | |||
TMPK-01442 |
HLA-A*02:01&B2M&P53 WT (HMTEVVRRC) Tetramer Protein, Human, MHC (His & Avi), PE-Labeled
HLA-A,P53,TP53,LFS1,MHC,BCC7,TRP53,FLJ9294... |
Human | HEK293 Cells |
p53 is a tumor suppressor protein. Under stressful conditions, p53 tightly regulates cell growth by promoting apoptosis and DNA repair. When p53 becomes mutated, it loses its function, resulting in abnormal cell proliferation and tumor progression. Depending on the p53 mutation, it has been shown to form aggregates leading to negative gain of function of the protein. p53 mutant associated aggregation has been observed in several cancer tissues and has been shown to promote tumor growth. | |||
TMPK-01445 |
HLA-A*02:01&B2M&MAGE-A1 (KVLEYVIKV) Monomer Protein, Human, MHC (His & Avi), Biotinylated
CT1.1,MAGE1,MAGE-1,MAGE-A |
Human | HEK293 Cells |
MAGE-A1 belongs to the chromosome X-clustered genes of cancer-testis antigen family and is normally expressed in the human germ line but is also overexpressed in various tumors. | |||
TMPK-01477 |
HLA-A*02:01&B2M&AFP (FMNKFIYEI) Monomer Protein, Human, MHC (His & Avi), Biotinylated
HPAFP,FETA,Alpha-1-fetop... |
Human | HEK293 Cells |
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response. | |||
TMPK-01493 |
HLA-A*01:01&B2M&MAGE-A3 (EVDPIGHLY) Tetramer Protein, Human, MHC (His & Avi)
MZ2-D,Melanoma-associate... |
Human | HEK293 Cells |
Melanoma antigen gene A3 (MAGE-A3) is one of the most immunogenic cancer testis antigens and is common in various types of cancers. MAGE-A3 can be considered as a predictor for poor prognosis and an option for vaccine immunotherapy in patients with PCa. | |||
TMPK-01458 |
HLA-A*11:01&B2M&KRAS G12A (VVVGAAGVGK) Monomer Protein, Human, MHC (His & Avi)
K-Ras 2,GTPase Kras,KRAS... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01539 |
HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Monomer Protein, Human, MHC (His & Avi), Biotinylated
CTAG1B,CT6.1,MY-ESO-1,LAGE2A,NY-E... |
Human | HEK293 Cells |
NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit spontaneous humoral and cellular immune responses, together with its restricted expression pattern, have rendered it a good candidate target for cancer immunotherapy. | |||
TMPK-01529 |
HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (His & Avi)
K-RAS4A,KRAS1,MHC,K-RAS2... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01484 |
HLA-A*02:03&B2M&AFP (FMNKFIYEI) Monomer Protein, Human, MHC (His & Avi)
HPAFP,FETA,AFP,AFPD,... |
Human | HEK293 Cells |
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response. | |||
TMPK-01449 |
HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Monomer Protein, Human, MHC (E. coli, His & Avi)
MHC,CT6.1,CTAG1,LAGE-2,MY-ESO-1,NY-ESO-1,E... |
Human | E. coli |
NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit spontaneous humoral and cellular immune responses, together with its restricted expression pattern, have rendered it a good candidate target for cancer immunotherapy. | |||
TMPK-01480 |
HLA-A*02:01&B2M&Survivin (LMLGEFLKL) Monomer Protein, Human, MHC (His & Avi), Biotinylated
IAP4,Survivin,API4,BIRC5,MHC,MHC I,EPR-1,s... |
Human | HEK293 Cells |
Survivin (also known as BIRC5) is an evolutionarily conserved eukaryotic protein that is essential for cell division and can inhibit cell death. Normally it is only expressed in actively proliferating cells, but is upregulated in most, if not all cancers; consequently, it has received significant attention as a potential oncotherapeutic target. | |||
TMPK-01404 |
HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated
NS,KRAS,KRAS1,KRAS2,MHC,RA |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01519 |
HLA-A*02:01&B2M&AFP (FMNKFIYEI) Tetramer Protein, Human, MHC (His & Avi)
MHC,FETA,AFP,Alpha-feto,... |
Human | HEK293 Cells |
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response. | |||
TMPK-01470 |
HLA-A*02:01&B2M&MAGE-A4 or MAGE-A8 (KVLEHVVRV) Monomer Protein, Human, MHC (His & Avi)
MAGE-A4 or MAGE-A8,M... |
Human | HEK293 Cells |
MAGE-A4 and MAGE-A8 are type I membes of the melanoma associated antigen (MAGE) family. The MAGE family is a large, highly conserved group of proteins that share a common MAGE homology domain. Both MAGE-A4 and MAGE-A8 antigen-presenting peptides can be presented by HLA-A*02:01. | |||
TMPK-01481 |
HLA-A*24:02&B2M&Survivin 2B (AYACNTSTL) Monomer Protein, Human, MHC (His & Avi), Biotinylated
svn 2B,svn-2B,Survivin-2B |
Human | HEK293 Cells |
Survivin-2B, a known splice variant of survivin, has been reported to promote cell death in some cancer cells, although it keeps prosurvival function in others.survivin-2B promoted autophagy and further regulated cell death by accumulating and stabilizing IKK alpha in the nucleus. | |||
TMPK-01494 |
HLA-A*01:01&B2M&CT83 (NTDNNLAVY) Tetramer Protein, Human, MHC (His & Avi)
HLA-A,HLA-A*0101,HLA... |
Human | HEK293 Cells |
Cancer/testis antigens 83 (CT83), also called KK-LC-1 or CXorf61, recognized by cytotoxic T lymphocytes (CTL), has become a promising target for immunotherapy. | |||
TMPK-01444 |
HLA-A*02:01&B2M&MAGE-A1 (KVLEYVIKV) Tetramer Protein, Human, MHC (His & Avi)
MZ2-E,MAGE1A,MAGE-1 anti... |
Human | HEK293 Cells |
MAGE-A1 belongs to the chromosome X-clustered genes of cancer-testis antigen family and is normally expressed in the human germ line but is also overexpressed in various tumors. | |||
TMPK-01530 |
HLA-A*02:01&B2M&LMP2 (CLGGLLTMV) Monomer Protein, Human, MHC (His & Avi), Biotinylated
MHC,LMP-2,PSMB9,LMP2,Macropain cha |
Human | HEK293 Cells |
The immunoproteasome, having been linked to neurodegenerative diseases and hematological cancers, has been shown to play an important role in MHC class I antigen presentation. The development of molecular probes that selectively inhibit the major catalytic subunit, LMP2, of the immunoproteasome,LMP2-rich cancer cells compared to LMP2-deficient cancer cells are more sensitive to growth inhibition by the LMP2-specific inhibitor, implicating an important role of LMP2 in regulating cell growth of ma... | |||
TMPK-01434 |
HLA-A*11:01&B2M&KRAS G12R (VVVGARGVGK) Tetramer Protein, Human, MHC (His & Avi)
RASK2,CFC2,GTPase Kras,KRA |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01525 |
HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
CFC2,RALD,K-Ras 2,MHC,C-K-RAS,NS3... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01520 |
HLA-A*02:01&B2M&AFP (PLFQVPEPV) Tetramer Protein, Human, MHC (His & Avi)
Alpha-1-fetoprotein,AFP,HPA |
Human | HEK293 Cells |
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response. | |||
TMPK-01474 |
HLA-A*24:02&B2M&MAGE-A3 (IMPKAGLLI) Monomer Protein, Human, MHC (His & Avi)
|
Human | HEK293 Cells |
Melanoma antigen gene A3 (MAGE-A3) is one of the most immunogenic cancer testis antigens and is common in various types of cancers. MAGE-A3 can be considered as a predictor for poor prognosis and an option for vaccine immunotherapy in patients with PCa. | |||
TMPK-01513 |
HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Monomer Protein, Human, MHC (His & Avi), Biotinylated
CT6.1,LAGE2A,MHC,CTAG1B,CTA |
Human | HEK293 Cells |
NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit spontaneous humoral and cellular immune responses, together with its restricted expression pattern, have rendered it a good candidate target for cancer immunotherapy. | |||
TMPK-01403 |
HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi)
K-Ras 2,KI-RAS,CFC2,KRAS1,GTP... |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01448 |
HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Tetramer Protein, Human, MHC (E. coli, His & Avi)
MHC,LAGE-2,NY-ESO-1,ESO1CTAG,MY-ESO-1,CT |
Human | E. coli |
NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit spontaneous humoral and cellular immune responses, together with its restricted expression pattern, have rendered it a good candidate target for cancer immunotherapy. | |||
TMPK-01467 |
HLA-A*02:01&B2M&HPV 16 E6 (KLPQLCTEL) Monomer Protein, Human, MHC (His & Avi)
HPV16,E6,Human papillomavirus typ... |
Human | HEK293 Cells |
Human papillomavirus (HPV) 16 infection is a necessary condition for the pathogenesis and development of cervical cancer. The E6 protein is expressed by the HPV16 E6 gene and promotes malignant phenotype transformation, which is an important mechanism for the occurrence and development of cervical cancer. | |||
TMPK-01446 |
HLA-A*02:01&B2M&MAGE-A1 (KVLEYVIKV) Monomer Protein, Human, MHC (His & Avi)
MAGE1,MAGE1A,MAGE-1 ... |
Human | HEK293 Cells |
MAGE-A1 belongs to the chromosome X-clustered genes of cancer-testis antigen family and is normally expressed in the human germ line but is also overexpressed in various tumors. | |||
TMPK-01399 |
HLA-A*11:01&B2M&KRAS WT (VVGAGGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
K-RAS2A,NS3,KRAS2,CFC2,K-RA |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. | |||
------------------------ 更多 ------------------------ |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T12210 |
Netupitant D6
CID-6451149 D6 |
Others | Others |
Netupitant D6 is the deuterium labeled Netupitant, which is a selective and orally active antagonist of neurokinin-1 receptor. | |||
TMIJ-0519 |
Fosaprepitant-d4 Dimeglumine
|
||
Fosaprepitant-d4 Dimeglumine 是 Fosaprepitant Dimeglumine 的氘代化合物。Fosaprepitant Dimeglumine 的 CAS 号为 265121-04-8。Fosaprepitant dimeglumine 是 Aprepitant 的前药。它是一种神经激肽 1 受体拮抗剂,可用于预防化疗引起的恶心呕吐。 |